Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Key Drivers of Market Growth: Several factors are driving the rapid expansion of the global cell and gene therapy market. Technological advancements, particularly in gene editing techniques such as ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

在生物科技公司面临挑战的一年里，CRISPR Therapeutics AG的股票在更广泛的市场下跌中跌至52周低点，触及38.2美元。根据 InvestingPro 的数据，该公司保持"良好"的整体财务健康评分，其资产负债表显示现金多于债务，表现尤为强劲。这家以基因编辑开创性工作而闻名的公司，过去一年股价大幅回落38.23%。这一下跌反映了投资者对监管障碍、临床试验进度以及基因编辑疗法盈利能力的 ...

CobbleStone Software?a recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrixtm Report?is excited to share its four-step process for document generation and some ...

本文基于CRISPR Therapeutics AG的新闻稿。该股票的贝塔系数为1.67，显示出比大盘更高的波动性，这对新兴生物技术公司来说是典型的。要深入了解CRISPR Therapeutics的财务健康状况和增长前景，包括独家分析和公允价值估计，请查看InvestingPro上提供的全面专业研究报告 ...

Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...